Meet the Team
Our team brings over 100 years of accumulative experience in the pharma industry supporting patients globally on receiving broader and faster access to breakthrough therapies.
With global experience and expertise our team are highly committed to supporting our global expansion to reach as many patients suffering from rare disease.
Our passionate team mission is to improve the lives of patients with rare disease knowing that with Arphio they will be forever rare but not alone.
Chairman of the Board
Anil is the Chairman of the Board at Arphio, CCO of Alvotech and GM and Board Member of Adalvo. Anil comes with an impressive track record as a general manager, P&L owner, commercial operations professional and expert negotiator, completing countless license, acquisition, supply, distribution, and sales and marketing agreements, worth >$25B. Over the course of his 15-year career in the pharmaceutical industry, Anil developed an extensive network and deep expertise in Commercial Operations, BD and M&A. Anil plays an integral role in building and establishing Arphio’s go-to-market strategy, securing partnerships in more than 100 countries worldwide. Concurrently, he started Adalvo in 2018 and built it up to becoming one of the leading B2B companies in Europe.
Anil is the CCO of Alvotech and GM and Board Member of Adalvo. He previously served as the Head of Global Licensing for HELM AG where he managed all partnerships for small molecules in addition to biosimilars through a joint venture with Gedeon Richter, resulting in the most successful commercial performance in the company’s 40-year history. He also held positions of increasing responsibility at Abdi Ibrahim, in various regions and functions, eventually heading all international market operations where he developed and led the successful execution of a global market entry strategy including more than 30 new markets. He began his career at Sanofi as a medical rep and transitioned to business development.
Anil holds an MBA from the Vienna University of Economics and Business and a Master of Marketing Management from Galatasaray University. He completed a Bachelor of Engineering with a double major in Mathematics and Computer Engineering, graduating with honors. He has continued honing his skillset through various executive education programs at Harvard and INSEAD.
Anil was recognized “Leader of the Year” at the 2021 Global Generics and Biosimilars Awards.
Dr. Shlomo Sadoun
CEO / Member of the Board
A savvy pharma entrepreneur with over 16 years of experience in the pharmaceutical industry, Shlomo is the Founder of SK-Pharma Group and the main stakeholder and founder of TrioxBio, a clinical stage orphan drug company that holds orphan drugs designation and fast track designation from the FDA for IDH.
Influenced by technology from the excellent startup nation of Israel, Shlomo proudly embraces data driven decisions, based on patient centric approach. Shlomo is passionate about orphan drugs mission, of making drugs accessible globally to patient with unmet needs. Shlomo had devoted the last 5 years into research over the most impacting factors (the six pillars of success) that can secure patient access to orphan drugs and maximize the drugs commercialization potential.
Shlomo performed his Doctoral Degree in the Royal Academy of Economics and Technology in Switzerland, in public health management, focusing his research on practical, applicable methodology for the successful launch of orphan drugs in the US and Europe. Shlomo completed his master’s degree in Salford University Manchester in global management, focusing his thesis on the important factors impacting a successful IPO of biotech companies in the US and Europe.
VP Market Access / Member of the Board
Martina is member of the board and Vice President of Regulatory Affairs.
Martina brings overall more than 20 years of experience in the industry. She has been working across global regulatory setup for over 15 years. Managing teams in practically all continents Martina successfully brought several thousands of MA’s including a number of proprietary, 505b2/hybrid and complex products.
During her career, she was able to bring innovative and proprietary products to full regulatory approval earlier than those products could be granted an EU regulatory approval.
VP Portfolio / Member of the Board
Istvan is member of the board of Arphio and responsible for portfolio and business development activities.
Istvan brings 15 years of experience in the industry. Throughout his career he has been involved in managing portfolio and product securement for various regional and global companies. His interest lies mainly with complex and orphan products where he brings a solid track record navigating in various commercial regions from Europe to Asia-Pacific. Istvan brings a broad knowledge when it comes to product assessment, market evaluation and competitive intelligence.
Istvan holds an M.sc in Economics and an MBA in Business Management.
Vyara is the Chief Financial Officer of Arphio.
Vyara has more than 10 years experience in Finance. She started her career in Financial Advisory with Deloitte and has lead a number of high profile transactions in various industries, building strong business acumen. During the past 5 years she has been heading the Finance and FP&A functions in global pharmaceutical companies. Vyara is highly focused on digital transformation and automation in organisations.
VP Business Development
Miloš is responsible for global business development in the Asia Pacific (APAC), Middle East and North Africa (MENA), Central and Eastern Europe (CEE) and Russia & CIS.
With experience in multinational pharmaceutical companies, Miloš brings broad knowledge and extensive skills in business development, strategic partnerships, acquisitions, and opening new markets.
His last experience includes partnering with innovative multinational companies in introducing novel therapies and covering unmet needs in several markets.
Besides broad pharma experience along with Project Management Professional (PMP)® certification, Miloš has an academic background in economics.
Business Development Director
Tarun is responsible for global business development and out-licensing of Arphio’s product portfolio. He is experienced in BD&L, market access strategy, regulatory landscape analysis and competitive intelligence. Having worked in large multinational pharmaceutical companies, he brings in vast experience and successful track record of deal making globally. Tarun is a registered Pharmacist (India) and hold a Doctorate (Ph.D.) in Molecular Toxicology from a De Montfort University, UK, followed by a post-Doctoral research degree in Drug Repurposing.
Senior BD Specialist
Helena is responsible for global business development, identifying new growth opportunities and strategic long-term collaborations for the organization in the fields of Oncology, Hematology and Immunology. Helena holds over 10 years of marketing and sales experience in multinational pharmaceutical companies, such as AbbVie and Novartis.
Helena has substantial experience in business development projects as well as managing complete product life cycle. She has substantial experience in launching new products including introduction to new markets in various medical fields as well as managing Named Patient Program.
Helena holds a B.sc in Biology and MBA in Business Management & International Marketing
Milan is responsible for business development, identifying new growth opportunities and creating long-term value for the organization. With more than 15 years of marketing and sales experience; in multinational pharmaceutical companies, such as AbbVie and Sanofi; Milan brings broad knowledge and extensive skills; in business development, market evaluation and competitive intelligence to the company. Milan has vast experience in leading teams to success in the fields of oncology, hematology, nephrology, diabetology, anesthesia and more. Milan holds a unique combination of experience along with an academic background in medicine.